SEC Form 4 · accession 0001797672-26-000004
Nautilus Biotechnology, Inc. · NAUT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen Akinsanya
Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 22, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001808805
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.28 | Jun 18, 2026 | A | 45,000 | A | — | Jun 18, 2036 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).